The availability of “healthy” human hematopoietic CD34+ progenitor cells and retroviral vector technology facilitates the establishment of models used to analyze human leukemic CD34+ progenitor cell expansion driven by leukemia-associated gene products. This evidence concerns the gene CD34 and leukemia.